Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT07347769Recruiting
BK virus risk study in kidney transplant patients
This study looks at the type and genetic makeup of BK virus in kidney transplant patients and their donors. It aims to find patients at higher risk for a kidney infection caused by the virus, which could help improve monitoring and treatment.
GrenobleAges 18 years+ - NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT05839314RecruitingPhase 4
Huaier granules for idiopathic membranous nephropathy with PLA2R
This trial studies whether Huaier granules can improve kidney disease activity in people with “idiopathic membranous nephropathy” who test positive for PLA2R antibodies and are still not in remission. Participants will also have been on standard blood-pressure/kidney-protecting treatment (called RASI) for at least 4 weeks.
Beijing, Beijing MunicipalityAges 18–75 - NCT06760845Recruiting
Using light to diagnose kidney disease
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Jinan, ShandongAges Any age - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT03929887Recruiting
Kidney biopsy patients join a kidney tissue research bank
This study builds a kidney tissue “library” to help researchers analyze kidney disease in newer ways. It may help by improving how glomerular (kidney filter) diseases are understood over time, using samples from people who already had a biopsy.
ChuncheonAges Any age - NCT04931537Recruiting
Testing early kidney marker tests for people with diabetes
This study looks for early warning signs in blood or other samples (using a special lab approach) to detect kidney problems sooner in people with diabetes. It may help patients and clinicians identify kidney risk earlier and follow changes over many years.
HangzhouAges 18–80 - NCT05888909Recruiting
Tests better diagnosis and treatment planning for kidney disease in type 2 diabetes
This trial focuses on improving how kidney damage is diagnosed and how treatment is planned for people with type 2 diabetes and kidney disease. It may help by using detailed medical history and (if done) kidney biopsy results to guide care more accurately.
BeijingAges 18 years+ - NCT04557462RecruitingPhase 3
Long-term safety study of iptacopan for IgA nephropathy
This study provides continuing treatment with iptacopan for people with IgA nephropathy who have completed a previous iptacopan trial. It aims to see how safe and tolerable the drug is over a longer period.
Glendale, ArizonaAges 18–100 - NCT07861204RecruitingPhase 2/Phase 3
Combination treatment for primary membranous nephropathy
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
BeijingAges 18–80 - NCT05514015RecruitingPhase 4
Rituximab with steroids or rituximab alone for membranous kidney disease
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Guangzhou, GuangdongAges 18–75 - NCT07822152RecruitingPhase 1
Cord blood stem cells for diabetic kidney disease
This trial tests whether injecting stem cells from donated umbilical cords can help people with kidney damage caused by type 2 diabetes. The goal is to see if this treatment can slow the decline in kidney function and safely improve their condition.
WuhanAges 30–70 - NCT07807995Enrolling by invitationPhase 3
Long-term treatment for IgA nephropathy
This study tests a medication called povetacicept for long-term use in adults with IgA nephropathy, a kidney disease. If you've already completed the earlier study, this trial aims to see how well the drug works over a longer period to help keep your kidneys working longer.
Arvada, ColoradoAges 18 years+ - NCT07764991RecruitingPhase 2
Lactoferrin supplement for diabetic kidney disease
This study tests whether taking a lactoferrin supplement can help people with type 2 diabetes and chronic kidney disease (stage 3 or 4) by reducing protein in their urine, which is a sign of kidney damage. It may offer a new way to slow the progression of kidney disease.
CairoAges 18–75 - NCT07750249Enrolling by invitationEarly Phase 1
Short-chain fatty acids for IgA nephropathy
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
MartinAges 18 years+ - NCT05775042RecruitingPhase 2
CM338 for immunoglobulin A kidney disease
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
Beijing, Beijing MunicipalityAges 18–75 - NCT06661174Recruiting
Weight loss surgery study for diabetes with kidney problems
This study tests if bariatric surgery can help people whose diabetes is quickly damaging their kidneys. It may slow down kidney disease and improve health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07616700RecruitingPhase 2
Long-term safety study of HSK39297 for IgA kidney disease
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
BeijingAges Any age - NCT07604311RecruitingPhase 4
Preventing IgA nephropathy flare-ups with Nefecon
This study tests whether continuing Nefecon after initial treatment helps prevent IgA nephropathy (a kidney disease) from coming back. If you have already been on Nefecon for at least 9 months and your protein levels are low now, you might be able to join.
Guangzhou, GuangdongAges 18–75 - NCT07582133RecruitingPhase 2
Long-term safety study of HRS-5965 for IgA kidney disease
This study follows up on patients who participated in a previous trial (HRS-5965-305) testing a drug called HRS-5965 for IgA nephropathy, a kidney disease where the immune system damages the kidneys. Researchers want to check if the drug continues to be safe and well-tolerated over a longer period.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07541287RecruitingPhase 2
JADE101 for IgA Nephropathy Kidney Disease
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Chula Vista, CaliforniaAges 18–60 - NCT07498673RecruitingEarly Phase 1
Testing YKST02 for IgA nephropathy
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
Wuhan, HubeiAges 18–75 - NCT07444203Recruiting
Study of kidney tissue in diabetes-related kidney disease
This study collects and studies kidney tissue (from a biopsy or surgery) from people with diabetes-related kidney disease to learn more about the condition. You may be able to help if you've already had a kidney biopsy or certain kidney surgeries.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 151 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.